

WSA Planning Meeting  
October 6-10, 2003  
DRAFT - FOR DISCUSSION PURPOSES ONLY

N01352	Investigating the Potential Applicability of Compromised Animal Models of Cigarette Smoke-Induced Emphysema	Vanscheeuwijck, P	Priority				
<b>EVALUATION</b>							
<b>EVALUATION FRAMEWORK</b>							
<b>NON-CLINICAL (cont.)</b>							
PROJECT NUMBER	PROJECT NAME	PROJECT LEADER	PRIORITY	Original Completion Date	Previous Completion Date	Revised Completion Date	COMMENTS
<b>CVD</b>							
N01120	CVD Biomarkers Evaluation	Schleef, R	Critical				
N01357	Method Development, CVD Biomarkers, Biochemistry	Kuhl, P	Critical				
N01358	Combined Smoke Inhalation and Feeding Study on Knockout Mouse Model of Atherosclerosis/Arteriothrombosis	Schleef, R	Critical				
N01401	Exercise Performance of Adults Smoking ACCORD or Conventional Cigarettes	Unverdorben, M.	Critical				
N01402	Influence of Smoking the EHCSS ACCORD® on Endothelium-Dependent Venoreactivity	Unverdorben, M.	Critical				
N01423	Organ Bath Model System for CVD	Schleef, R	Critical				
N01424	Thrombosis Animal Model	Schleef, R	Critical				
N01356	Cardiac Telemetry Methods	Meurrens, K	Priority				
N01359	Joint Smoke Inhalation Pilot Study with German Heart Center and Other Groups	Von Holt, K	Priority				
N01422	Animal Models for Studying the Impact of Multiple Risk Factors on Cardiovascular Disease (CVD)	Schleef, R	Priority				
N01360	Proteomics of Serum to Identify Endpoints with Relevance for CVD	Schepers, G	Priority				
N01188	Flow cytometric assays for investigating cytotoxicity/apoptosis	Kindt, R	Priority				
<b>REPRO</b>							
N01433	Reduced Birth Weight Validation/MAO	Carmines, E	Priority				
N01439	In vitro Models for low birth weight	Carmines, E	Priority				
<b>DETERMINANTS OF EXPOSURE</b>							
N01405	Genomics/Proteomics Approaches - Differential Gene Expression	Davies, B	Critical				

1501 F02 air G6 H Clinical

1501 = 03/31/04 6/30/03 5/31/03

Red - Identified as Critical  
Green - Kept as Critical  
Blue - Priority or Secondary

WSA Planning Meeting  
October 6-10, 2003  
DRAFT - FOR DISCUSSION PURPOSES ONLY

N01352	Investigating the Potential Applicability of Compromised Animal Models of Cigarette Smoke-Induced Emphysema	Vanscheeuwijck, P	Priority				
<b>EVALUATION</b>							
<b>EVALUATION FRAMEWORK</b>							
<b>NON-CLINICAL (cont.)</b>							
PROJECT NUMBER	PROJECT NAME	PROJECT LEADER	PRIORITY	Original Completion Date	Previous Completion Date	Revised Completion Date	COMMENTS
<b>CVD</b>							
N01120	CVD Biomarkers Evaluation	Schleef, R	Critical				
N01357	Method Development, CVD Biomarkers, Biochemistry	Kuhl, P	Critical				
N01358	Combined Smoke Inhalation and Feeding Study on Knockout Mouse Model of Atherosclerosis/Arteriothrombosis	Schleef, R	Critical				
N01401	Exercise Performance of Adults Smoking ACCORD or Conventional Cigarettes	Unverdorben, M.	Critical	01/01/03	06/24/03	07/31/03	
N01402	Influence of Smoking the EHCSS ACCORD® on Endothelium-Dependent Venoreactivity	Unverdorben, M.	Critical				
N01423	Organ Bath Model System for CVD	Schleef, R	Critical				
N01424	Thrombosis Animal Model	Schleef, R	Critical				
N01356	Cardiac Telemetry Methods	Meurrens, K	Priority				
N01359	Joint Smoke Inhalation Pilot Study with German Heart Center and Other Groups	Von Holt, K	Priority				
N01422	Animal Models for Studying the Impact of Multiple Risk Factors on Cardiovascular Disease (CVD)	Schleef, R	Priority				
N01360	Proteomics of Serum to Identify Endpoints with Relevance for CVD	Schepers, G	Priority				
N01188	Flow cytometric assays for investigating cytotoxicity/apoptosis	Kindt, R	Priority				
<b>REPRO</b>							
N01433	Reduced Birth Weight Validation/MAO	Carmines, E	Priority				
N01439	In vitro Models for low birth weight	Carmines, E	Priority				
<b>DETERMINANTS OF EXPOSURE</b>							
N01405	Genomics/Proteomics Approaches - Differential Gene Expression	Davies, B	Critical				

*1501+2 are critical*

WSA Planning Meeting  
October 6-10, 2003  
DRAFT - FOR DISCUSSION PURPOSES ONLY

EVALUATION							
EVALUATION FRAMEWORK							
CLINICAL							
PROJECT NUMBER	PROJECT NAME	PROJECT LEADER	PRIORITY	Original Completion Date	Previous Completion Date	Revised Completion Date	COMMENTS
<b>CANCER</b>							
N01462	Review of NCI database and other literature for functional genomics and/or proteomic studies characterizing early biomarkers for lung cancer	Sarkar, M.	Critical				
<b>COPD</b>							
N01395	Development of an Inflammation/Irritation Model for the Human Upper Respiratory Tract	Kobal, G	Critical	9/15/047			
N01465	Mucociliary Clearance (MCC)	<del>Mendes, P.</del> H. G. 207	Priority				
N01487	Biomarkers of inflammation in Bronchoalveolar lavage fluid	Mendes, P.	Priority				
<b>CVD</b>							
N01435	Confirm the observation of endothelial dysfunction arising from acute ETS exposure; use results to develop a clinical assay to assess "reduced ETS" prototypes; and identify ETS components responsible for observed effects	Sanders, E	Critical				
N01455	Assessment of exercise performance of non/no-smokers exposed to ETS	Unverdorben, M. <del>Sanders, E.</del>	Priority				
N01466	Early Biomarkers of Inflammation	Unverdorben, M.	Priority				
N01489	Influence of Smoking PREPs on Left Ventricular Diastolic Function	Unverdorben, M.	Priority				
N01490	Influence of Smoking versus No-smoking on Intima-Media-Thickness	Unverdorben, M.	Priority				
<b>DETERMINANTS OF EXPOSURE</b>							
N01457	Method Development for Retention Study	Nelson, B	Critical	9/15/2004			

Accept  
JLI Long Term WTSY studies

Nov 2008

PM3005219187

WSA Planning Meeting  
October 6-10, 2003  
DRAFT - FOR DISCUSSION PURPOSES ONLY

EVALUATION							
EVALUATION FRAMEWORK							
CLINICAL							
PROJECT NUMBER	PROJECT NAME	PROJECT LEADER	PRIORITY	Original Completion Date	Previous Completion Date	Revised Completion Date	COMMENTS
GENERAL							
	Clinical Study Guidelines		Critical				
N01459	TES Follow-up Study	Oey, J	Critical				
N01458	Method development for retention study	Feng, S.	Critical	12/31/03	12/31/03	12/31/03	
N01470	Longitudinal Clinical Risk Evaluation Study	Roethig, H	Critical				NEED UPDATED PROJECT SHEET
N01491	Marlboro Short Term Full Flavor Exposure	Gogova, M Mendes, P	Critical				
N01492	Marlboro Full Flavor Long Term	Gogova, M Mendes, P	Critical				
N01460	Characterization of enzyme induction as an early biomarker of potential harm	Sarkar, M.	Priority				
N01456	Non-linear modeling of biomarkers from the Multi-Center Total Exposure Study	Nelson, B	Priority				
N01467	Statistical data mining to provide alternative clinical trial designs for PREP Evaluation	Liang, Q.	Priority				
N01468	Statistical approaches for developing overall exposure reduction scores	Liang, Q.	Priority				
N01488	Bronchial hyperresponsiveness	Mendes, P.	Priority				
N01104	Haemoglobin Adducts of Aromatic Amines (AA)	Schorp, M	Secondary				

PM3005219188

7489

3

PM3005219189